BE2016C069I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C069I2
BE2016C069I2 BE2016C069C BE2016C069C BE2016C069I2 BE 2016C069 I2 BE2016C069 I2 BE 2016C069I2 BE 2016C069 C BE2016C069 C BE 2016C069C BE 2016C069 C BE2016C069 C BE 2016C069C BE 2016C069 I2 BE2016C069 I2 BE 2016C069I2
Authority
BE
Belgium
Application number
BE2016C069C
Other languages
French (fr)
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of BE2016C069I2 publication Critical patent/BE2016C069I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BE2016C069C 2002-01-28 2016-12-12 BE2016C069I2 (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
BE2016C069I2 true BE2016C069I2 (is) 2022-05-17

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C069C BE2016C069I2 (is) 2002-01-28 2016-12-12

Country Status (45)

Country Link
US (4) US7612087B2 (is)
EP (2) EP1480644B1 (is)
JP (1) JP4472346B2 (is)
KR (1) KR100979079B1 (is)
CN (3) CN101406471A (is)
AR (2) AR038234A1 (is)
AT (1) ATE484281T1 (is)
AU (1) AU2003214335B2 (is)
BE (1) BE2016C069I2 (is)
BR (1) BRPI0307267B8 (is)
CA (1) CA2474043C (is)
CL (1) CL2011000009A1 (is)
CO (1) CO5601014A2 (is)
CR (2) CR7387A (is)
CY (3) CY1111061T1 (is)
DE (1) DE60334527D1 (is)
DK (2) DK2279737T3 (is)
EA (1) EA007220B1 (is)
EC (1) ECSP045193A (is)
ES (2) ES2401855T3 (is)
FR (1) FR2835186B1 (is)
HK (2) HK1077205A1 (is)
HR (1) HRP20040686B1 (is)
HU (1) HUS1600055I1 (is)
IL (1) IL163167A (is)
JO (1) JO2646B1 (is)
LT (1) LTC1480644I2 (is)
MA (1) MA26351A1 (is)
MX (1) MXPA04006621A (is)
MY (1) MY140638A (is)
NL (1) NL300847I2 (is)
NO (2) NO335195B1 (is)
NZ (1) NZ533936A (is)
OA (1) OA12761A (is)
PE (1) PE20030969A1 (is)
PL (1) PL220725B1 (is)
PT (2) PT2279737E (is)
RS (1) RS52137B (is)
SI (2) SI2279737T1 (is)
TN (1) TNSN04137A1 (is)
TW (1) TWI293071B (is)
UA (1) UA80271C2 (is)
UY (1) UY27626A1 (is)
WO (1) WO2003063864A2 (is)
ZA (1) ZA200405607B (is)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
CA2783572C (en) * 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
EP2078027A1 (en) * 2006-10-23 2009-07-15 Irm Llc Cathepsin proteases inhibitors
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
WO2009091856A2 (en) * 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2346820B1 (en) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
EP2748165B1 (en) * 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
MX349827B (es) * 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8962843B2 (en) 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8927724B2 (en) 2012-03-30 2015-01-06 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105859609B (zh) 2012-05-30 2019-04-09 明治制果药业株式会社 β-内酰胺酶抑制剂及其制备方法
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6329147B2 (ja) * 2012-08-25 2018-05-23 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
MY193210A (en) 2013-09-24 2022-09-26 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US10131665B2 (en) 2013-10-08 2018-11-20 Meiji Seika Pharma Co., Ltd. Processes for producing diazabicyclooctane compounds
CN106029068A (zh) * 2014-02-20 2016-10-12 沃克哈特有限公司 包含抗菌剂的药物组合
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
JP6672176B2 (ja) 2014-05-19 2020-03-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6767392B2 (ja) * 2015-05-07 2020-10-14 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及び細菌感染の治療又は予防におけるその使用
CA2984024A1 (en) 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
TW201725205A (zh) 2015-10-02 2017-07-16 樂高化學生物科學股份有限公司 用於抑制β-內醯胺酶之組合物及方法
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
CN114591223A (zh) 2016-09-16 2022-06-07 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
TW201831482A (zh) 2017-02-06 2018-09-01 法商木塔比利斯公司 新穎雜環化合物及其預防或治療細菌感染之用途
KR102611447B1 (ko) 2017-05-08 2023-12-06 엔타시스 테라퓨틱스, 인크. 박테리아 감염을 치료하는 화합물 및 방법
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
EP3694864A4 (en) 2017-10-11 2021-10-13 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND THEIR SYNTHESIS
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
CN116375706A (zh) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
DK0724587T3 (da) 1993-09-29 2003-01-06 Nabi Nukleosider og nukleotider med forstørrede ringe
KR100197454B1 (ko) * 1993-12-29 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 디아자비시클릭 뉴로키닌 길항제
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
IL124912A0 (en) * 1996-01-03 1999-01-26 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
EP1070054A1 (en) 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
AR021716A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
ATE361750T1 (de) 2001-02-22 2007-06-15 Univ London Pharmacy Indoline und tetrahydro-chinoline als prodrugs zur tumorbehandlung
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
MA26351A1 (fr) 2004-10-01
TNSN04137A1 (fr) 2007-03-12
NO20043587L (no) 2004-08-27
JO2646B1 (en) 2012-06-17
HRP20040686B1 (hr) 2013-02-28
KR100979079B1 (ko) 2010-08-31
HRP20040686A2 (en) 2004-12-31
SI2279737T1 (sl) 2013-07-31
US7612087B2 (en) 2009-11-03
UY27626A1 (es) 2003-08-29
LTPA2016037I1 (lt) 2017-01-10
CN1994301A (zh) 2007-07-11
WO2003063864A2 (fr) 2003-08-07
NO2016024I2 (no) 2016-12-15
CA2474043A1 (fr) 2003-08-07
DE60334527D1 (de) 2010-11-25
LTC1480644I2 (lt) 2018-09-10
TWI293071B (en) 2008-02-01
BRPI0307267B8 (pt) 2021-05-25
PT1480644E (pt) 2011-01-17
HUS1600055I1 (hu) 2017-01-30
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
DK2279737T3 (da) 2013-02-11
US20110245254A1 (en) 2011-10-06
NO2016024I1 (no) 2016-12-15
ATE484281T1 (de) 2010-10-15
EP2279737B1 (fr) 2012-10-31
CA2474043C (fr) 2011-08-02
CY1114417T1 (el) 2016-08-31
ES2401855T3 (es) 2013-04-25
US20090215747A1 (en) 2009-08-27
CN101406471A (zh) 2009-04-15
SI1480644T1 (sl) 2011-03-31
BR0307267A (pt) 2004-12-07
PT2279737E (pt) 2013-02-01
DK1480644T3 (da) 2011-01-24
AR038234A1 (es) 2005-01-05
CY2016042I2 (el) 2017-03-15
CN100563653C (zh) 2009-12-02
PL220725B1 (pl) 2015-12-31
MY140638A (en) 2010-01-15
UA80271C2 (uk) 2007-09-10
ECSP045193A (es) 2004-08-27
CN100482225C (zh) 2009-04-29
HK1077205A1 (en) 2006-02-10
AU2003214335B2 (en) 2007-04-05
JP4472346B2 (ja) 2010-06-02
NO335195B1 (no) 2014-10-20
KR20040081473A (ko) 2004-09-21
EA007220B1 (ru) 2006-08-25
HK1105864A1 (en) 2008-02-29
FR2835186A1 (fr) 2003-08-01
RS52137B (en) 2012-08-31
US20050020572A1 (en) 2005-01-27
US20100048528A1 (en) 2010-02-25
CR7387A (es) 2010-10-25
AR100790A2 (es) 2016-11-02
NZ533936A (en) 2007-05-31
MXPA04006621A (es) 2004-10-04
CY1111061T1 (el) 2015-06-11
WO2003063864A3 (fr) 2004-03-11
FR2835186B1 (fr) 2006-10-20
OA12761A (fr) 2006-07-04
IL163167A (en) 2010-04-15
ZA200405607B (en) 2005-09-28
CO5601014A2 (es) 2006-01-31
CY2016042I1 (el) 2017-03-15
BRPI0307267B1 (pt) 2016-02-10
JP2005523897A (ja) 2005-08-11
EP1480644B1 (fr) 2010-10-13
YU65804A (sh) 2006-08-17
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
NL300847I2 (is) 2017-01-03
CL2011000009A1 (es) 2011-03-25
ES2356813T3 (es) 2011-04-13
EP2279737A1 (fr) 2011-02-02
PL371601A1 (en) 2005-06-27
CN1655781A (zh) 2005-08-17
EA200400981A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
BE2019C547I2 (is)
BE2019C510I2 (is)
BE2018C021I2 (is)
BE2017C005I2 (is)
BE2016C069I2 (is)
BE2016C013I2 (is)
BE2018C018I2 (is)
BE2016C002I2 (is)
JP2003247966A5 (is)
JP2003160408A5 (is)
BRPI0215435A2 (is)
JP2003126679A5 (is)
DE60330807D1 (is)
JP2003216450A5 (is)
JP2003247937A5 (is)
HU0202638D0 (is)
JP2003015161A5 (is)
JP2003235059A5 (is)
JP2003241524A5 (is)
JP2003190578A5 (is)
BR0315835A2 (is)
JP2003060608A5 (is)
JP2003024610A5 (is)
CH694599C1 (is)
AU2002227782A1 (is)